Protective immunity against porcine circovirus 2 in mice induced by a gene-based combination vaccination

Journal of Gene Medicine

Volumn 11, Issue 4, 2009, Pages 288-301

  Aravindaram, Kandan ^a   Kuo, Tsun Yung ^b   Lan, Chun Wen ^a   Yu, Hsiu Hui ^a   Wang, Pei Hsueh ^a   Chen, Yu San ^b   Chen, Gabriel Hsu Chung ^b   Yang, Ning Sun ^a  

^a AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^b NATIONAL ILAN UNIVERSITY   (Taiwan)

Author keywords

Cellular immunity; Gene gun; Humoral immunity; Porcine circovirus; Prime boost; Vaccine

Indexed keywords

CHEMOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; NAKED DNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CIRCOVIRIDAE; CROSS REACTION; CYTOKINE RELEASE; DNA VECTOR; FEMALE; GENE GUN; GENETIC IMMUNIZATION; MOUSE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; T LYMPHOCYTE; VIRUS INFECTION; VIRUS TITRATION;

ANIMALS; CIRCOVIRIDAE INFECTIONS; CIRCOVIRUS; CYTOKINES; DNA, VIRAL; GENE THERAPY; IMMUNITY; MICE; MICE, INBRED BALB C; PORCINE POSTWEANING MULTISYSTEMIC WASTING SYNDROME; SWINE; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, COMBINED; VACCINIA VIRUS;

MUS; PORCINE CIRCOVIRUS; PORCINE CIRCOVIRUS 2; SUIDAE; VACCINIA VIRUS ANKARA;

EID: 65949113396     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1300     Document Type: Article

References (64)

1. Tischer I, Gelderblom H, Vettermann W, Koch MA. A very small porcine virus with circular single-stranded DNA. Nature 1982; 295: 64-66.
2. Clark EG. Post-weaning multisystemic wasting syndrome. Proc Am Assoc Swine Pract 1997; 28: 499-501.
3. Allan GM, McNeilly F, Kennedy S, et al. Isolation of porcine circovirus-like viruses from pigs with a wasting disease in the USA and Europe. J Vet Diagn Invest 1998; 10: 3-10.
4. Choi C, Chae C, Clark EG. Porcine postweaning multisystemic wasting syndrome in Korean pig: detection of porcine circovirus 2 infection by immunohistochemistry and polymerase chain reaction. J Vet Diagn Invest 2000; 12: 151-153.
5. Fenaux M, Halbur PG, Gill M, Toth TE, Meng XJ. Genetic characterization of type 2 porcine circovirus (PCV-2) from pigs with postweaning multisystemic wasting syndrome in different geographic regions of North America and development of a differential PCR-restriction fragment length polymorphism assay to detect and differentiate between infections with PCV-1 and PCV-2. J Clin Microbiol 2000; 38: 2494-2503.
6. Mankertz A, Domingo M, Folch JM, et al. Characterization of PCV2 isolates from Spain, Germany, and France. Virus Res 2000; 66: 65-77.
7. Kim J, Chung HK, Jung T, Cho WS, Choi C, Chae C. Postweaning multisystemic wasting syndrome of pigs in Korea: prevalence, microscopic lesions and coexisting microorganisms. J Vet Med Sci 2002; 64: 57-62.
8. Balasch M, Segales J, Rosell C, et al. Experimental inoculation of conventional pigs with tissue homogenates from pigs with postweaning multisystemic wasting syndrome. J Comp Pathol 1999; 121: 139-148.
9. Albina E, Truong C, Hutet E, et al. An experimental model for postweaning multisystemic wasting syndrome (PMWS) in growing piglets. J Comp Pathol 2001; 125: 292-303.
10. Bolin SR, Stoffregen WC, Nayar GP, Hamel AL. Postweaning multisystemic wasting syndrome induced after experimental inoculation of cesarean-derived, colostrum-deprived piglets with type 2 porcine circovirus. J Vet Diagn Invest 2001; 13: 185-194.
11. Fenaux M, Opriessnig T, Halbur PG, Elvinger F, Meng XJ. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs. J Virol 2004; 78: 6297-6303.
12. Liu J, Chen I, Du Q, Chua H, Kwang J. The ORF-3 protein of porcine circovirus type 2 is involved in viral pathogenesis in vivo. J Virol 2006; 80: 5065-5073.
13. Opriessnig T, Yu S, Gallup JM, et al. Effect of vaccination with selective bacterins on conventional pigs infected with type 2 porcine circovirus. Vet Pathol 2003; 40: 521-529.
14. Segales J, Domingo M. Porcine dermatitis and nephropathy syndrome: a porcine circovirus type 2 infection disease. PMWS Symposium, 16th International Pig Veterinarians Society Congress. Melbourne, Australia, 2000; 21-31.
15. Cheung AK. Transcriptional analysis of porcine circovirus. Virology 2003; 305: 168-180.
16. Mankertz A, Mankertz J, Wolf K, Buhk HJ. Identification of a protein essential for replication of porcine circovirus. J Gen Virol 1998; 79: 381-383.
17. Nawagitgul P,Morozov I, Bolin SR, Harms PA, Sorden SD. Open reading frame 2 of porcine cicovirus type 2 encodes a major capsid protein. J Gen Virol 2000; 81: 2281-2287.
18. Liu J, Chen I, Kwang J. Characterization of a previously unidentified viral protein in porcine circovirus type 2-infected cells and its role in virus-induced apoptosis. J Virol 2005; 79: 8262-8274.
19. Blanchard P, Mahé D, Cariolet R, et al. Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV2) proteins. Vaccine 2003; 21: 4565-4575.
20. Kamstrup S, Barfoed AM, Frimann TH, Mikkelsen ASL, Bøtner A. Immunization against PCV2 structural protein by DNA vaccination of mice. Vaccine 2004; 22: 1358-1361.
21. Wang X, Jiang P, Li Y, Jiang W, Dong X. Protection of pigs against post-weaning multisystemic wasting syndrome by a recombinant adenovirus expressing the capsid protein of porcine circovirus type 2. Vet Microbiol 2007; 121: 215-224.
22. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) [author's translation]. Dtsch Med Wochenschr 1974; 99: 2386-2392.
23. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991; 72: 1031-1038.
24. Moss B. Replicating and host-restricted non-replicating vaccinia virus vectors for vaccine development. Dev Biol Stand 1994; 82: 55-63.
25. Parrino J, McCurdy LH, Larkin DB, et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax®. challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 2007; 25: 1513-1525.
26. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292: 69-74.
27. + T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus. Immunol Cell Biol 2001; 79: 569-575.
28. McConkey SJ, Reece WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9: 729-735.
29. McShane H. Developing an improved vaccine against tuberculosis. Expert Rev Vaccines 2004; 3: 299-306.
30. Mwau M, Cebere I, Sutton J, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85: 911-919.
31. Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 2003; 3: 263-271.
32. Vollmar J, Arndtz N, Eckl KM, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2005; 24: 2065-2070.
33. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006; 12: 3416-3424.
34. Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 2004; 15: 506-512.
35. Cosma A, Nagaraj R, Bühler S, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003; 22: 21-29.
36. Takada A, Kuboki N, Okazaki K, et al. A virulent avian influenza virus as a vaccine strain against a potential human pandemic. J Virol 1999; 73: 8303-8307.
37. Staib C, Drexler I, Sutter G. Construction and isolation of recombinant MVA. Methods Mol Biol 2004; 269: 77-100.
38. Moss B, Carroll MW, Wyatt LS, et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 1996; 397: 7-13.
39. DrexlerI, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Virol 1998; 79: 347-352.
40. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998; 5: 397-402.
41. + T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001; 69: 681-686.
42. McNair I, Marshall M, McNeilly F, et al. Interlaboratory testing of porcine sera for antibodies to porcine circovirus type 2. J Vet Diagn Invest 2004; 16: 164-166.
43. Wyatt LS, Shors ST, Murphy BR, Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 1996; 14: 1451-1458.
44. Earl PL, Moss B, Wyatt LS, et al. Generation of recombinant vaccinia virus. In Current Protocols in Molecular Biology, Ausubel FM, Brent R, Kingston RE, et al (eds), Vol. 2. Greene Publishing Associates &Wiley Interscience: New York, NY, 1998; 16.17.1-16.17.19.
45. Rakhmilevich AL, Turner J, Ford MJ, et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996; 93: 6291-6296.
46. Harrington LE, Most Rv R, Whitton JL, Ahmed R. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 2002; 76: 3329-3337.
47. + T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 2005; 201: 95-104.
48. Staib C, Kisling S, Erfle V, Sutter G. Inactivation of the viral interleukin 1β receptor improves CD8+T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol 2005; 86: 1997-2006.
49. Kiupel M, Stevenson GW, Choi J, Latimer KS, Kanitz CL, Mittal SK. Viral replication and lesions in BALB/c mice experimentally inoculated with porcine circovirus isolated from a pig with post-weaning multisystemic wasting syndrome. Vet Pathol 2001; 38: 74-82.
50. Liu C, Ihara T, Nunoya T, Veda S. Development of an ELISA based on the baculovirus-expressed capsid protein of porcine circovirus type 2 as antigen. J Vet Med Sci 2004; 66: 237-242.
51. Herd KA, Harvey T, Khromykh AA, Tindle RW. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumor. Virology 2004; 319: 237-248.
52. Stevenson PG, Doherty PC. Kinetic analysis of the specific host response to a murine gamma herpesvirus. J Virol 1998; 72: 943-949.
53. Acres B, Gantzer M, Remy C, et al. Fusokine interleukin-2/ interleukin-18, a novel potent innate and adaptive immune stimulator with decreased toxicity. Cancer Res 2005; 65: 9536-9546.
54. Nayar GP, Hamel AL, Linn L, Sachvie C, Grudeski E, Spearman G. Evidence for circovirus in cattle with respiratory disease and from aborted bovine fetuses. Can Vet J 1999; 40: 277-278.
55. Tischer I, Bode L, Apodaca J, et al. Presence of antibodies reacting with porcine circovirus in sera of humans, mice, and cattle. Arch Virol 1995; 140: 1427-1439.
56. Kiupel M, Stevenson GW, Choi J, Latimer KS, Kanitz CL, Mittal SK. Viral replication and lesions in BALB/c mice experimentally inoculated with porcine circovirus isolated from a pig with post-weaning multisystemic wasting syndrome. Vet Pathol 2001; 38: 74-82.
57. Quintana J, Balasch M, Segale's J, et al. Experimental inoculation of porcine circoviruses type 1 (PCV1) and type 2 (PCV2) in rabbits and mice. Vet Res 2002; 33: 229-237.
58. Meerts P, Misinzo G, Lefebvre D, et al. Correlation between the presence of neutralizing antibodies against porcine circovirus type 2 (PCV2) and protection against replication of the virus and development of PCV2-assoicated disease. BMC Vet Res 2006; 30: 6-9.
59. Jonjic S, Val MD, Keil GM, Reddehase MJ, Koszinowski UH. A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol 1988; 62: 1653-1658.
60. Schall TJ. Biology of the RANTES/SIS cytokine family. Cytokine 1991; 3: 165-183.
61. Ward SG, Westwick J. Chemokines: understanding their role in T-lymphocyte biology. J Biochem 1998; 333: 457.
62. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-42.
63. + T cells. Science 1995; 270: 1811-1815.
64. Power UF, Huss T, Michaud V, Plotnicky-Gilquin H, Bonnefoy JY, Nguyen TN. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice. J Virol 2001; 75: 12421-12430.